LSD1 mediates metabolic reprogramming by glucocorticoids during myogenic differentiation. Issue 11 (29th March 2018)

• Record Type: Journal Article
• Authors: Anan, Kotaro; Hino, Shinjiro; Shimizu, Noriaki; Sakamoto, Akihisa; Nagaoka, Katsuya; Takase, Ryuta; Kohrogi, Kensaku; Araki, Hirotaka; Hino, Yuko; Usuki, Shingo; Oki, Shinya; Tanaka, Hirotoshi; Nakamura, Kimitoshi; Endo, Fumio; Nakao, Mitsuyoshi
• Is Part Of: Nucleic acids research. Volume 46:Issue 11(2018)
• Page Start: 5441
• Page End: 5454
• Publication Date: 2018-03-29
• Subjects: Nucleic acids -- Periodicals; Molecular biology -- Periodicals; 572.805
• DOI: 10.1093/nar/gky234
• Languages: English
• ISSNs: 0305-1048

Abstract

Abstract: The metabolic properties of cells are formed under the influence of environmental factors such as nutrients and hormones. Although such a metabolic program is likely initiated through epigenetic mechanisms, the direct links between metabolic cues and activities of chromatin modifiers remain largely unknown. In this study, we show that lysine-specific demethylase-1 (LSD1) controls the metabolic program in myogenic differentiation, under the action of catabolic hormone, glucocorticoids. By using transcriptomic and epigenomic approaches, we revealed that LSD1 bound to oxidative metabolism and slow-twitch myosin genes, and repressed their expression. Consistent with this, loss of LSD1 activity during differentiation enhanced the oxidative capacity of myotubes. By testing the effects of various hormones, we found that LSD1 levels were decreased by treatment with the glucocorticoid dexamethasone (Dex) in cultured myoblasts and in skeletal muscle from mice. Mechanistically, glucocorticoid signaling induced expression of a ubiquitin E3 ligase, JADE-2, which was responsible for proteasomal degradation of LSD1. Consequently, in differentiating myoblasts, chemical inhibition of LSD1, in combination with Dex treatment, synergistically de-repressed oxidative metabolism genes, concomitant with increased histone H3 lysine 4 methylation at these loci. These findings demonstrated that LSD1 serves as an epigenetic regulator linking glucocorticoid action to metabolic programming during myogenic differentiation.